Dose‐dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity

AIMS: LIK066 (licogliflozin) is a dual sodium glucose co‐transporter 1/2 inhibitor with potential benefits in weight loss. This study evaluated the efficacy, tolerability and safety of licogliflozin in Japanese adults with obesity. MATERIALS AND METHODS: This study was a randomized, double‐blind, pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokote, Koutaro, Sano, Misako, Tsumiyama, Isao, Keefe, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328287/
https://www.ncbi.nlm.nih.gov/pubmed/32072763
http://dx.doi.org/10.1111/dom.14006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328287/
https://www.ncbi.nlm.nih.gov/pubmed/32072763
http://dx.doi.org/10.1111/dom.14006

Ejemplares similares